Back to search

National and Kapodistrian University of Athens

Mελέτη της δραστικότητας in vitro των συνδυασμών καρβαπενέμης – κολιμυκίνης όπως και πιπερακιλλίνης/ ταζομπακτάμης – κολιμυκίνης έναντι στελεχών εντεροβακτηριακών που παράγουν μέταλλο-β-λακταμάσες

Abstract

dc:description

INTRODUCTIONDuring the past decade, metallo-beta-lactamases (MBLs) of VIM type have been expanded throughout Enterobacteriaceae, putting in danger the activity of carbapenems as well as other β-lactams. Antibiotics such as carbapenems (imipenem, meropenem and ertapenem) are extremely useful for treating hospital acquired infections, as they are active against bacteria that produce extended spectrum β-lactamases (ESBLs) and therefore they are non-susceptible to all other beta-lactams. In Greece, the continually rising incidence of VIM-1 Klebsiella pneumoniae in the Intensive Care Units has created an endemic situation. Additionally, sporadic cases as well as epidemics due to MBL- producing Enterobacteriaceae have been reported to all five continents. Acquired resistance to carbapenems has been reported in our country since late 1990s in Pseudomonas aeruginosa strains that produced VIM-2 and rarely VIM-4 MBL. In 2002 an epidemic of VIM-1 producing Klebsiella pneumoniae strains was reported in many hospitals in Athens.Two main groups of MBLs have been recognized, VIM type and IMP type, and according to recent references they have global geographic distribution. The genes that encode MBLs are situated in gene cassettes that are been found between integrons type 1. Therefore, the transmission from one strain to another is favored as well as the horizontal dispersion of these genes. The co-existence of MBL and ESBL in the same isolate complicates further the situation and requires additional attention. The majority of blaVIM carrying K. pneumoniae isolates have ΜΙCs that are included in the susceptibility breakpoints for carbapenems, according to the suggested criteria by CLSI.Regarding multi-drug resistant isolates, only colistin and tigecycline are considered to be active in vitro. Tigecycline exhibits in vitro activity against Gram negative bacteria producing MBL, but references concerning in vivo activity are still limited. Furthermore, the lack of activity against P. aeruginosa limits its use as empirical monotherapy in critically ill patients in Intensive Care Units. On the other hand, regarding colistin, references about either the clinical outcome of its use as monotherapy or the pharmacokinetics and pharmacodynamics are limited. Additionally, the recent acknowledgment of the existence of strains of K. pneumoniae resistant to colistin endangers the outcome of the already limited treatment choices for infections in Intensive Care Units. For all these reasons, the use of combinations with several antibiotics in hospitals with relatively high percentages of MBL- producing bacteria is a common empiric choice.The clinical data regarding the best treatment of infections caused by MBL- producing Enterobacteriaceae, even those with low level MICs are internationally limited. The broad spectrum of hydrolysis of these enzymes limits down the treatment choices and it is unknown whether the combination of a carbapenem or piperacillin/tazobactam with colistin is active and exhibits synergy in vitro.MATERIALS AND METHODSWe examined 45 clinical isolates of MBL – producing K. pneumoniae isolated from patients that had being hospitalized in the University General Hospital “Attikon” and in the Intensive Care Unit of General Hospital “Evaggelismos” from February 2004 to September 2006. The majority of these isolates originate from blood cultures and bronchial secretions and the rest from urine, pus or feces. As a result, the majority of them caused clinical infections and not only colonization. Only one isolate from each patient was included in the study, except from isolates that went through epidemiological identification and was ensured to be different clones. The identification was performed with the classic methods of clinical microbiology and with the use of biochemical tests (API20E system, bioMérieux, Marcy L’Ėtoile, France). The determination of the susceptibilities to imipenem, meropenem, ertapenem, piperacillin/tazobactam and colistin was performed by Etest (AB Biodisc, Solna, Sweden). The phenotypic test for detecting the production of MBL was performed by the EDTA-imipenem synergy test. The presence of the blaVIM was confirmed by PCR. On the basis of PCR-restriction fragment length polymorphism analysis, all isolates carried the blaVIM-1-type gene. ESBL production was detected with the CLSI confirmatory test with slide modification.In vitro interactions between imipenem and colistin, meropenem and colistin, ertapenem and colistin, piperacillin/tazobactam and colistin were tested using time-kill methodology. Antibiotic concentrations used were 10μg/ml for imipenem, meropenem and ertapenem, 35/7μg/ml for piperacillin/tazobactam and 5μg/ml for colistin sulfate, because these concentrations represent the steady state achievable in human serum during treatment and thus are clinically relevant. For susceptible strains, if 4× MIC was not higher than the above mentioned concentrations, this concentration was also tested. The counting of living colonies of the isolates was performed on hours 0, 1, 3, 5 and 24.Synergy was defined as a ≥2-log10 decrease in CFU/ml between the combination and the most active single agent at the different time points, with the number of surviving organisms in the presence of the combination being ≥2 log10 CFU/ml below the number of organisms in the starting inoculum. Antagonism was defined as a ≥2-log10 increase in CFU/ml between the combination and the most active single agent. All other interactions were characterized as indifferent. Bactericidal activity of single antibiotics or combinations was defined as a ≥3-log10 reduction in the CFU/ml of the initial inoculum after 24h of incubation. The lower limit of detection was 1.6 log10 CFU/ml.In order to evaluate the development of resistance as a reason for bacterial regrowth after 24h of incubation with the studied combination, viable colonies were subjected to susceptibility testing in comparison with the respective wild-type strain, using agar dilution as described by CLSI. This evaluation was performed only for isolates that were initially susceptible to at least one of the tested antimicrobials.The chi-square test was used to compare proportions of killing activity or synergy between groups by using Yates continuity correction in two-by-two tables. P values of <0.05 were considered statistically significant.RESULTS45 genetically different isolates of blaVIM-1 producing K. pneumoniae were tested for the activity of the combinations imipenem-colistin, meropenem-colistin, ertapenem-colistin, piperacillin/tazobactam-colistin according to the above described methodology. In all isolates the presence of MBL was detected by the EDTA-imipenem synergy test and was confirmed by PCR. Susceptibilities to imipenem, meropenem, ertapenem, piperacillin/tazobactam and colistin were evaluated according to CLSI breakpoints for the first four and EUCAST for colistin. Results of time killing curves experiments using concentrations of antibiotics described above, were as follows: The imipenem-colistin combination regarding colistin susceptible isolates exhibited synergy against 16 out of 52 different combinations of concentrations tested (30.8%) and only one (1.9%) exhibited antagonism. Regarding non-colistin-susceptible isolates, 10 out of 19 different combinations of concentrations tested exhibited antagonism (52.6%) and only two of them synergy (10.5%). These two isolates had low MIC in colistin (4μg/ml). When the imipenem-colistin combination was performed in colistin susceptible isolates, bactericidal activity was observed in a statistically higher percentage comparing to each antibiotic alone (78.9% against 20.7% for imipenem, p<0.0001 and against 46.2% for colistin, p=0.001). For non-colistin-susceptible isolates the combination did not seem to be better regarding bactericidal activity. After exposure to the imipenem-colistin combination, in none of the imipenem susceptible isolates was observed development of resistance, while among the colistin susceptible isolates a resistant clone developed in 15.4% of them.The meropenem-colistin combination regarding colistin susceptible isolates exhibited synergy against 25% and antagonism against 9.6% out of the 52 different combinations of concentrations tested. Regarding non-colistin-susceptible isolates, 10.5% exhibited synergy and 15.8% antagonism out of the 19 different combinations of concentrations tested. When this combination was performed in colistin susceptible isolates, bactericidal activity was observed in a statistically higher percentage comparing to each antibiotic alone (69.2% against 13.8% for meropenem, p<0.0001 and against 46.2% for colistin, p=0.029). For non-colistin-susceptible isolates, neither each antibiotic alone nor the combination exhibited bactericidal activity. After exposure to the meropenem-colistin combination, 20% of the isolates with MIC≤4μg/ml in meropenem developed resistance to meropenem and 23.1% of the colistin-susceptible isolates developed resistance to colistin.The ertapenem-colistin combination regarding colistin susceptible isolates exhibited synergy against 32.7% and antagonism against 5.8% out of the 52 different combinations of concentrations tested. Regarding non-colistin-susceptible isolates, 5.3% exhibited synergy and 31.6% antagonism out of the 19 different combinations of concentrations tested. When this combination was performed in colistin susceptible isolates, bactericidal activity was observed in a statistically higher percentage comparing to each antibiotic alone (78.9% against 23.1% for ertapenem, p<0.0001 and against 46.2% for colistin, p=0.0001). For non-colistin-susceptible isolates, there was not a statistically important difference comparing the bactericidal activity of each antibiotic alone and the combination. After exposure to the ertapenem-colistin combination, one isolate (11.1%) developed resistance to ertapenem and 19.2% of the colistin-susceptible isolates developed resistance to colistin.The piperacillin/tazobactam-colistin combination regarding colistin susceptible isolates exhibited synergy against 44% and antagonism against 12%, while indifference was observed in all non-colistin-susceptible isolates. When the combination was performed in colistin susceptible isolates, bactericidal activity was observed in a percentage of 68%, which was statistically higher comparing to piperacillin/tazobactam alone (4%), but not statistically higher comparing to colistin alone (40%). For non-colistin-susceptible isolates, there was not observed bactericidal activity neither with each antibiotic alone nor with the combination.DISCUSSIONAccording to the results described above regarding the imipenem-colistin combination, it is safe to be used against isolates either susceptible or with low level resistance to colistin (MIC ≤4 μg/ml), as synergy, better bactericidal activity and protection from the development of resistant to imipenem clones are expected. The use of this combination should be avoided in isolates with high level resistance to colistin (MIC ≥8 μg/ml), as it could cause antagonism and is not beneficial regarding bactericidal activity.The meropenem-colistin combination is regarded to be beneficial comparing to each antibiotic alone for isolates susceptible to colistin, as better bactericidal activity is expected comparing to meropenem alone. For non-colistin-susceptible isolates, the combination is regarded to be non-beneficial.The ertapenem-colistin combination seems to be beneficial regarding synergy and better bactericidal activity, mainly against colistin-susceptible isolates, while it also seems to provide protection from the development of ertapenem-resistant clones. For non-colistin-susceptible isolates, the combination is regarded to be non-beneficial, in the contrary it can result to antagonism in high percentage.Regarding the piperacillin/tazobactam-colistin combination, it results to synergy and bactericidal activity only when it is used for colistin-susceptible isolates.Despite the fact that combinations of colistin and carbapenems are being widely used in clinical practice, they have not being studied enough in vitro, while there is no data from experimental models in animals about their advantages against monotherapy. Additionally, there is poor data about isolates producing VIM MBLs, as this study is unique. Even though it seems that the results are depending on the specific characteristics of each isolate, the observation that high level resistance to colistin has negative results on the expected outcome of the combination is stable and is most probably of clinical significance. The accurate detection of MIC to colistin is of great importance in order to decide either in favor or against the use of these combinations.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Rekatsina, Panagiota-Danai
  • Ρεκατσίνα, Παναγιώτα-Δανάη

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40306

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Rekatsina, Panagiota-Danai; Ρεκατσίνα, Παναγιώτα-Δανάη. Mελέτη της δραστικότητας in vitro των συνδυασμών καρβαπενέμης – κολιμυκίνης όπως και πιπερακιλλίνης/ ταζομπακτάμης – κολιμυκίνης έναντι στελεχών εντεροβακτηριακών που παράγουν μέταλλο-β-λακταμάσες. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/40306